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Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-
acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma
(PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with
advanced, unresectable PDAC (n= 27), ATRA is re-purposed as a stromal-targeting agent in
combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive con-
tinual re-assessment method trial design. The maximum tolerated dose (MTD) and
recommended phase 2 dose (RP2D, primary outcome) is the FDA/EMEA approved dose of
gemcitabine-nab-paclitaxel along-with ATRA (45mg/m2 orally, days 1–15/cycle). Dose
limiting toxicity (DLT) is grade 4 thrombocytopenia (n= 2). Secondary outcomes show no
detriment to ATRA pharmacokinetics.. Median overall survival for RP2D treated evaluable
population, is 11.7 months (95%CI 8.6–15.7 m, n= 15, locally advanced (2) and metastatic
(13)). Exploratory pharmacodynamics studies including changes in diffusion-weighted (DW)-
MRI measured apparent diffusion coefficient after one cycle, and, modulation of cycle-specific
serum pentraxin 3 levels over various cycles indicate stromal modulation. Baseline stromal-
specific retinoid transport protein (FABP5, CRABP2) expression may be predicitve of
response. Re-purposing ATRA as a stromal-targeting agent with gemcitabine-nab-paclitaxel
is safe and tolerable. This combination will be evaluated in a phase II randomized controlled
trial for locally advanced PDAC. Clinical trial numbers: EudraCT: 2015-002662-23;
NCT03307148. Trial acronym: STARPAC.
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Advanced pancreatic ductal adenocarcinoma (PDAC) has adismal prognosis with modestly effective treatmentoptions. Desmoplastic stroma and hypo-vascularity, dis-
tinctive features of PDAC, impede successful delivery of che-
motherapeutic drugs. Pancreatic stellate cells (PSC), critical
components and instigators of desmoplasia, mediate cancer cell
pro-survival and pro-invasive capabilities through multiple sig-
naling cascades1. This tumor–stroma cross-talk is unlikely to be
blocked effectively by merely targeting a single pathway. Targeting
the multi-faceted tumor-promoting cancer–stromal cell interac-
tions (i.e., normalizing the desmoplastic stroma) may, however,
enhance the effectiveness of conventional chemotherapy.
Patients with PDAC display fat-soluble vitamin deficiencies
due to impaired biliary and pancreatic secretions. Although
vitamin K deficiency is manifested and treated clinically, the lack
of vitamin A2, which is not recognized clinically, may perpetuate
PSC activation. In a healthy pancreas, PSC store a metabolite
[retinoic acid (RA)] of vitamin A (retinol). When activated, in
cancer or inflammation, PSC lose RA stores and assume an
activated myofibroblast phenotype1. Furthermore, RA also is a
vital molecule regulating key signaling pathways guiding
embryonic pancreas development3,4; signaling cascades that are
hijacked during pancreatic carcinogenesis.
Based on these observations, we demonstrated, using various
PDAC models, that restoring RA depots within PSC, using all-
trans retinoic acid (ATRA), limited the desmoplasia and sup-
pressed cancer growth1,5–7. Furthermore, we established that
activated PSC impede the migration of immune cells, such as
CD8+ T cells, natural killer, and B cells, into the immediate
PDAC microenvironment; a process that was reversed by ATRA5.
ATRA is an ideal agent to dampen multiple, amplified,
embryonic, context-specific signaling cascades activated in
PDAC7,8. ATRA, but not 9-cis- or 13-cis-retinoic acid, reduces
PSC proliferation by G1 cell-cycle arrest with accumulation of
lipid droplets, thus restoring their normal physiological role.
Specificity of retinoid (RAR) and rexinoid (RXR) receptor iso-
forms, distinctly used and regulated by various RA, is vital in
pancreatic embryogenesis and PSC biology9. Our data suggest a
specific upregulation of RARβ isoform by ATRA7. This is rele-
vant, since 13-cis-RA has previously been found to be ineffective,
in combination with either gemcitabine10 or interferon11 in
patients with PDAC.
Since only ATRA is relevant to PSC physiology and embryonic
development of the pancreas, here we re-purpose ATRA as a
stromal-targeting agent, in combination with one of the widely
used standard-of-care chemotherapy12 in a phase Ib clinical trial.
We demonstrate that ATRA is a stromal targeting agent by
conducting pharmacokinetic and pharmacodynamic studies to
discover specific biomarkers while determining recommended
phase 2 dose (RP2D).
Results
Trial design and enrollment. We used an innovative two-step,
adaptive, Bayesian continual reassessment method using five
potential dose levels (DL) which appears to have advantages over
standard 3+ 3 and titeCRM designs in accurately predicting
RP2D, based on priors of toxicity data13 (Fig. 1, Supplementary
Fig. 1, and Supplementary Table 1). A total of 32 patients were
screened to enroll 28 of whom 27 received any treatment from
February 2016 to February 2018. Final data collection cut-off for
clinical parameters was 1 April 2019.
Primary and secondary outcomes. We demonstrated that the
FDA/EMEA-approved doses of gemcitabine (G, 1000 mg/m2 iv)
and nab-paclitaxel (nP, 125 mg/m2 iv), both on days 1, 8, and 15
of each 28-day cycle (PDAC12), can be combined safely with the
recommended dose of ATRA (for acute promyelocytic leukemia,
APML14) at 45 mg/m2 orally in two divided doses from days 1 to
15 of each cycle in patients with PDAC, resulting in an acceptable
toxicity and side-effect profile (DL5, Table 1, Figs. 1 and 2, and
Supplementary Tables 1–5). Thus, the primary outcome of
maximum tolerated dose (MTD) and RP2D was DL5. Two
patients had dose-limiting toxicities of grade 4 thrombocytopenia
(one patient each at DLs 3 and 5). Among secondary outcomes
on safety and tolerability, neurotoxicity, characteristically seen
with nab-paclitaxel treatment, appeared to be reduced by ATRA,
in frequency and intensity, an aspect to be explored in larger
randomized studies. This feature was previously reported in the
context of lung cancer15, although with no underlying mechan-
istic explanation16.
Furthermore, patients treated at the MTD demonstrated
encouraging evidence of response when assessed by best response
of change in the target lesion sum of diameters compared to
DL3 (n = 2),
1 DLT
DL2 (n = 3),
0 DLT
DL4 (n = 3),
0 DLT
Analysis based on
STARPAC trial design
STARPAC (part 2),
13 patients screened
STARPAC (part 1),
19 patients screened
3 screen
failures
1 screen failure,
1 withdrawn
RP2D = DL5 MTD = DL5
DL5 (n = 9),
1 DLT
Fig. 1 CONSORT diagram for STARPAC clinical trial. Number of patients at all dose levels (DL) in dose escalation, part 1 (using the STARPAC adaptive
trial design13) for maximum tolerated dose (MTD) estimation, showing dose-limiting toxicity (DLT) and dose expansion (part 2) of the trial for optimal
biological dose (OBD) estimation leading to recommended phase 2 dose (RP2D).
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baseline (Fig. 2b). Median progression-free survival (PFS) was
6.4 months (95% CI, 3.5 months–not reached (NR)) and median
overall survival (OS) was 10.9 months (95% CI, 8.6 months–NR)
(Supplementary Table 4) in the evaluable population (receiving at
least two cycles of this combination or progressing within the first
two cycles, n= 15) analysis restricted to pre-specified follow-up
for 12 months only for RP2D. Post hoc analysis of these patients
(n= 15), of data beyond 12 months, showed that the median OS
of 11.7 months (95% CI, 8.6–15.7 months) for RP2D may be
superior to the reported (8.5 months, 95% CI: 7.9–9.5 months)
for metastatic PDAC in the phase III clinical trial with
gemcitabine–nab-paclitaxel12. Additionally, four of these patients
(27%) went on to have second-line treatment (FOLFIRINOX,
FOLFIRI, FOLFOX, 5FU+ liposomal irinotecan (n= 1 for
each)), which was a lower proportion when compared to the
pivotal phase III trial (38–42%)12. Accepting that this is an early
phase I trial, these are promising results.
ATRA pharmacokinetics. The addition of chemotherapy did not
reduce plasma levels of ATRA (Fig. 3a, Supplementary Figs. 2 and
3, and Supplementary Tables 6 and 7) when compared to his-
torical data of single-agent ATRA at similar doses in patients
without PDAC17,18. The ATRA regimen at RP2D (at a dosing
and schedule optimized for APML19) resulted in consistent
plasma ATRA concentrations (AUC and Cmax) during successive
cycles, strongly suggesting lack of CYP26 enzyme induction, a key
factor limiting continued dosing with ATRA20. Patient com-
pliance with scheduling was excellent, with better median dose
intensities of both cytotoxic agents than previously reported in
the phase III trial for gemcitabine–nab-paclitaxel (Supplementary
Table 5)12.
Biochemical response and vitamin A levels. CA19-9 biochem-
ical responses are a reliable predictor of long-term survival in
PDAC12,21. While most patients (14/19 at RP2D) showed sig-
nificant early and sustained CA19-9 responses, we identified
five patients who had a poor CA19-9 response (Fig. 3b, c and
Supplementary Fig. 4). Plasma vitamin A levels for most
patients were maintained throughout all cycles, implying no
induction of CYP26 enzyme-mediated clearance. The five
patients who had poor CA19-9 responses exhibited either a
lower starting or a decline in levels of plasma vitamin A during
course of therapy, which upon linear regression analysis
demonstrated a downward trend as opposed to steady levels for
patients with a biochemical response (Fig. 3d–f and Supple-
mentary Fig. 5). This implies that plasma vitamin A levels could
potentially be a surrogate pharmacodynamic marker as a
composite readout of absorption and metabolism of retinol
which is upstream of, and therefore distinct from, ATRA
absorption and metabolism. An added benefit is the con-
venience of a routine assay in hospital laboratories. Optimal
biological dose (OBD) using vitamin A levels ≥1 and ≤2.5 µmol/
L, on a exploratory basis22, was achieved in 67–82% of patients
in each of the cycles (cycle 1 (72%, n= 18), cycle 2 (82%, n=
11), cycle 3 (82%, n= 11), cycle 4 (67%, n= 9), cycle 5 (75%,
n= 8), and cycle 6 (67%, n= 9)) for DL5 patients whom
vitamin A levels were available and excluding any patients who
had dose modifications from the point of modification onwards
(Supplementary Table 8). These data led to ATRA dosing, as
described in DL5, to be taken forward as RP2D.
Exploratory biomarkers: diffusion-weighted magnetic reso-
nance imaging (DW-MRI). Several potential biomarkers have
emerged from this phase I study which might be employed in
future studies. Since repeated biopsies of primary tumors are not
practical and may be ethically demanding, we used an imaging
biomarker as a surrogate for stromal activity. The dense cellular
stroma reduces tissue water content. DW-MRI allows derivation
of an apparent diffusion coefficient (ADC), which reflects extra-
and intra-cellular water mobility23, and can be a robust imaging
biomarker for response assessment in human tumors, if appro-
priately protocoled for cross-platform analysis (Supplementary
Tables 9 and 10 and Supplementary Fig. 6)24. Hence we evaluated
ATRA’s stromal effect using the true diffusion (D) component of
ADC. True diffusion (D) values demonstrated a consistent
increase as early as 1 month after treatment, indicating stromal
modulation, where there is no change in tumor volume, indi-
cating stromal modulation25, as observed in our preclinical
models7 (Fig. 4a–d).
Exploratory biomarkers: tissue assays. The baseline biopsies
assessed for RA transport molecules in cancer and stromal cell
compartments, demonstrated a differential distribution of fatty
acid-binding protein 5 (FABP5) and cellular RA-binding protein
2 (CRABP2)26, using a well-validated method to distinguish
stromal and epithelial compartments27, such that patients with
increased stromal expression of FABP5 were more likely to
achieve disease control (Fig. 4e–g, Supplementary Figs. 7 and 8,
and Supplementary Table 11). Thus the stromal expression of
FABP5 can be explored as a potential predictive biomarker.
Exploratory biomarkers: serum assays. Since we demonstrated
previously that pentraxin 3 gene (PTX3) is upregulated in acti-
vated PSC, and can be used as a potential diagnostic biomarker
for pancreatic cancer28, we explored whether serum PTX3 could
act as a stromal-response biomarker. An upregulation of serum
PTX3 within 5 h of administering ATRA on days 1 and 8 of the
first cycle, an effect lost by day 15, indicated that continuous
administration of ATRA may not have a sustained stromal effect
(Fig. 4h and Supplementary Fig. 9). Upregulation of serum PTX3
was not demonstrable by cycle 6 of the treatment when the
median serum PTX3 was at the upper limit of normal, as seen in
healthy subjects, perhaps indicating the maximum duration of
ATRA therapy should be 6 months (Fig. 4i). Serum PTX3 will be
explored further in the context of a planned randomized con-
trolled trial where comparisons can be made with non-ATRA
treated patients.
Table 1 Adverse events for STARPAC clinical trial.
Adverse events (AE) summary
DL5 patients All patients
Total patients (N) 19 27
AEs reported, n 470 638
Patients with at least one AE,
n
19 27
AEs per patienta, median
(range)
23 (8–71) 23 (8–71)
≥Grade 3 AEsa reported, n 33 55
Patients with at least one
≥Grade 3 AE, n
11 17
≥Grade 3 AEs per patienta,
median (range)
3 (1–5) 3 (1–9)
Distribution of AE. AE≥ grade 3 and DLTs in all patients and those receiving DL5 (RP2D)
according to SOC term, whether attributable or not to treatment. N= number of patients in the
Safety Set population for the specified group of patients.
aCounts of each instance, e.g., if one patient has the same term three times this is counted as
three instances.
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Discussion
The promising results of this phase I study support stromal nor-
malization as a valid approach in chemotherapeutically intractable
cancers such as PDAC. We demonstrate that repurposing ATRA as
a stromal-targeting agent, with gemcitabine–nab-paclitaxel, is safe
and tolerable with an exciting potential to enhance delivered che-
motherapy dose intensity, and mitigating some of the expected
adverse events, such as neurotoxicity, with evidence of putative
pharmacodynamic readouts. These features are in contrast to
recently publicized negative results of HALO 109-031 trial targeting
stroma using pegvorhyaluronidase alfa (PEGPH20), an agent which
potentially increases adverse events29.
This translation of preclinical work to a clinical application,
based on clinical observations and repurposing existing
drugs, should be tested in other diseases where stromal nor-
malization could impact clinical outcome. Based on the
encouraging response and survival data seen here, the efficacy
of this regimen will be evaluated in a phase II randomized
clinical trial in locally advanced PDAC (NCT04241276),
incorporating pharmacodynamic biomarkers for ATRA and
stromal targeting, and genomic readouts of tumoural30 and
stromal31 heterogeneity, which may play role in differential
response.
Registration to first treatment
R028
R009
R024
R027
R002
R010
R022
R018
R012
R023
R026
R001
R016
R020
R008
R011
R025
R015
R003
R007
R005
R014
R019
R021
R017
R029
R004
a
DL3
DL2
DL4
DL5
First treatment to last treatment
Last treatment to death or last date of contact
1210
Duration (months)
86
100100
80
60
40
20
0
–20
–40
–60
–80
–100
Pr
ob
ab
ilit
y 
of
 O
S 
(%
)
Be
st
 p
er
ce
nt
ag
e 
ch
an
ge
 in
 ta
rg
et
 le
sio
n
su
m
 o
f d
ia
m
et
er
s 
fro
m
 b
as
el
in
e 
(%
)
75
50
25
0
0 2 4 6 8 10
Time from registration (months)
Number at risk
12 14 16 18 20 22 24
15 15 14 14 14 10 7 3 1 1 1 1 0
420
b c
Fig. 2 Primary and secondary endpoints for STARPAC clinical trial. a Swimmer’s plot with color code for different dose levels (DL) and duration (months)
on X-axis along with type of disease: locally advanced (LA) and metastatic (M), those who experienced DLT (*) and disease status (Death (D), progressive
disease (PD)) censored at the pre-specified 12 months of starting on the trial. b Waterfall plot of best percentage change of sum of diameters in target
lesion from baseline in RP2D treated patients based on an evaluable population. A positive change denotes an increase in the target lesion sum of
diameters over time and, likewise, a negative change denotes a decrease in the target lesion sum of diameters over time. Reference lines added for
response (−30% change in target lesion sum of diameters) and progression (20% change in target lesion sum of diameters). RECIST responses are
marked with asterisk (*). There was progression for 6.7% (95% CI: 0.2–31.9%) and response in 46.7% (95% CI: 21.3–73.4%) of patients. c Post
hoc (including data from beyond 12 months) estimated median overall survival in 15 patients receiving RP2D on evaluable population basis. Number of
events= 13. Kaplan–Meier plot.
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Fig. 3 ATRA pharmacokinetics, biochemical CA19-9 response and vitamin A levels. a Serum ATRA levels for the first three cycles are summarized as
mean (SEM) for the first 5 h after co-administration of ATRA at 45mg/m2 with chemotherapy drugs. b Absolute CA19-9 levels on logarithmic Y-axis for
patients on dose level 5 at start of each cycle. Summary statistics represented by box (median ± interquartile range) and whisker (range: LQR−(1.5 × IQR)
and UQR+ (1.5 × IQR)). Two-sided Skilling–Mack test, statistic 39.21, p < 0.001. c Normalized CA19-9 levels for each patient on dose level 5 with baseline
being 100%. There were 14 biochemical responders (black) compared to 5 non-responders (unique colors). Responders are defined as those who show
>30% reduction of CA19-9 from baseline with a sustained response (no greater than 20% rise from previous reading at any time). d Vitamin A on dose
level 5 at start of each cycle. Summary statistics represented by box (median ± interquartile range) and whisker (range: LQR−(1.5 × IQR) and UQR+ (1.5 ×
IQR)). Two-sided Skilling–Mack test, statistic 5.95, p= 0.31. e Individual values for vitamin A for patients with biochemical non-responders (CA19-9)
highlighted in corresponding colors as in panel c. f Linear regression trend lines comparing biochemical responders (solid line) to non-responders (dashed
line) demonstrate that a drop in serum vitamin A levels may indicate non-responders. N= X R: X is the number of responders at the stated cycle. N= X NR:
X is the number of non-responders at the stated cycle.
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Methods
Trial design and patient population. STARPAC was an open-label, multicenter,
phase Ib study of ATRA administered with gemcitabine and nab-paclitaxel in
patients with locally advanced or metastatic pancreatic cancer, who had not
received prior systemic therapy for their disease. Additional eligibility criteria
included World Health Organization (WHO) performance status 0 or 1, life
expectancy ≥12 weeks, and adequate hematologic and end-organ function within
14 days prior to the first study treatment. Major exclusion criteria were known
brain metastases, pre-existing sensory neuropathy (>grade 1) and serious medical
risk factors involving any major organ systems, or serious psychiatric disorders,
which could compromise the patient’s safety or the study data integrity.
There were two parts to this study. In Part 1, a dose-escalation strategy using
the two-step adaptive Bayesian continual reassessment method (CRM)13 was used
to determine the MTD and the recommended dose to be taken forward in Part 2, a
dose expansion phase, to explore the OBD. OBD initially defined by vitamin A
levels between 1.5 and 2.5 μM (both inclusive) at each cycle was post-trial closure
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modified to levels of 1 and 2.5 μM (both inclusive) in line with National Institute of
Health’s Office of Dietary Supplements’ recommended levels22. OBD was estimated
at 80% of patients achieving serum vitamin A levels.
All patients provided written informed consent. Ethical approval for STARPAC
clinical trial: South Central-Berkshire Research Ethics Committee (REC); 15/SC/
0548 dated 13 October 2015 (Supplementary Note 1: Trial Protocol). STARPAC
trial was prospectively registered with EudraCT (2015-002662-23) on 11 June 2015
and clinical trial.gov (NCT03307148) on 11 October 2017. Trial opened to
recruitment on 20 January 2016. Three substantial amendments were made to
clinical trial protocol, and details are available on EudraCT. Permission for post
hoc analysis for data beyond 12 months of study was obtained from South Central-
Berkshire REC on 24 July 2019. All clinical data were collected on an in-house built
electronic Case Report Form (eCRF) designed using ORACLE v11.2.0. The study
was sponsored by Barts Health NHS Trust. The Centre for Experimental Cancer
Medicine (CECM), Barts Cancer Institute, Queen Mary University of London had
overall responsibility for trial management. The Trial Management Group (TMG)
was responsible for day-to-day running of the trial. Safety data were reviewed
regularly by the Safety Review Committee (SRC).
Statistical analysis. It was expected that a maximum of 24 evaluable patients
would be enrolled into Part 1 of the study based on CRM13. For Part 1, the primary
objective was to determine the MTD of the combination of gemcitabine–nab-
paclitaxel and ATRA, measured by the occurrence of DLTs during the first 28 days
of treatment that were attributed as possibly, probably, or definitely related to the
study treatment. For Part 2, a sample size of 10 was considered reasonable to
provide indicative data on OBD.
Secondary endpoints included analyses of PK parameters, response rates, PFS,
OS, and safety. For all time-to-event analyses performed, patients who did not have
an event were right censored: PFS censored on the last date the patient was known
to be progression free; OS censored at the date of last contact within 12 months of
enrollment into trial. Post hoc OS analysis was carried out for data beyond
12 months after REC approval to include data as there were exceptional survivors.
Survival endpoints were shown graphically with Kaplan–Meier plots.
All efficacy analyses were performed on the evaluable population which
included all patients receiving at least two cycles of the combination or progressing
within the first two cycles, regardless of whether they were later found to be
ineligible or a protocol violator. Safety analyses included all patients who received
at least one dose of study treatment. The worst grade of each adverse event (AE) for
each patient during study treatment was reported. Cumulative dose intensity over
the first six cycles was calculated as the actual amount of study drug received over
the first six cycles divided by the expected amount of study drug received over the
first six cycles. The expected amount of study drug was calculated based on the
dose and schedule specified in the study protocol.
Sample size calculations were performed using the software package PASS
version 12.0. All clinical efficacy endpoints were analyzed using STATA version
13.1. Laboratory data were analyzed using PRISM (GraphPad Inc) version 8.
Statistical tests are described as used.
Sample storage and traceability. All samples had a valid chain of custody
throughout procurement, temporary storage at site, shipping, and permanent
storage at the Barts Pancreas Tissue Bank (BPTB, REC Ref: 13/SC/0592, HTA
License number: 12199), and were given to laboratory staff via a traceable database,
in a blinded, anonymized manner.
Pharmacokinetic assays. ATRA, 9-cis-RA, and 13-cis-RA were purchased from
Sigma Aldrich (Poole, UK), and ATRA-d5 from Toronto Research Chemicals
(North York, Ontario, Canada). Liquid chromatography mobile phase solvents
(water, acetonitrile, and formic acid) were Optima grade, purchased from Fisher
Scientific (Loughborough, UK). An analytical method, using liquid
chromatography tandem mass spectrometry (LC-MS/MS), was established for the
measurement of ATRA concentrations in plasma. The method was subject to
EMEA validation procedures32. Validation of this method included precision and
accuracy, selectivity, specificity, matrix effects (including hemolytic and hyperli-
pidemic plasma), effect of co-medications, carryover, re-injectability, stability in
whole blood, stability of stock and working solutions and stability assessments in
plasma (24 h room temperature, 4 freeze/thaw cycles, and long-term frozen storage
at both −20 and −80 °C).
All analyses were done using an AB Sciex 6500 mass spectrometer (Warrington,
UK) equipped with a Nexera 2 LC-system (Shimadzu, MA, USA). Internal
standard ATRA-d5 was added to 10 µL of patient plasma sample. The plasma
proteins were precipitated using acetonitrile, followed by vortexing and
centrifugation. Supernatants (150 µL) were transferred to clean wells in a 96-well
plate, followed by the addition of 50 µL water and vortex mixing. Calibration
standards (calibration range 50–5000 ng/mL) and QC samples (100, 300, 800, and
4000 ng/mL) were prepared by the addition of ATRA to blank human plasma, and
then processed in the same manner as patient samples (Supplementary Fig. 2 and
Supplementary Table 7).
The extracts were analyzed by reversed phase chromatography (Acquity BEH
C18 UPLC column, Waters Corp., MA, USA), using gradient elution with
acetonitrile and 0.1% formic acid, at a flow rate 0.4 mL/min, total run duration
10 min. This was coupled to the MS/MS detector, operating in positive ion
atmospheric pressure chemical ionization mode. The MS/MS transitions for ATRA
and internal standard ATRA-d5 were m/z 301 > 205 and m/z 306 > 206,
respectively. The declustering potential, collision energy, and collision exit potential
were 40, 20, and 12 V, respectively, both for ATRA and ATRA-d5. A minimum of
six quality control samples were included in each LC-MS/MS run. ATRA
calibration standards were prepared in the calibration range 50–5000 ng/mL using
pooled human plasma. Standards and samples were assayed in the same manner
using the internal standard ATRA-d5. Quality control samples at 100, 300, 800,
and 4000 ng/mL were used to determine accuracy and precision (Supplementary
Fig. 2 and Supplementary Table 7).
Pharmacokinetic data were calculated using Prism software (GraphPad) and
validated against PCModfit software (http://pcmodfit.co.uk/nca.html) with
substitution of all “below limits of quantification” levels of ATRA at zero (range
could be zero to 62.5 ng/mL).
Diffusion-weighted magnetic resonance imaging. MRI was performed at two
institutions on multivendor platforms (Supplementary Table 9). Longitudinal
studies on the same patient were undertaken on the same scanner. The protocols
were developed to maximize signal-to-noise ratio and minimize ghosting and
distortion using a well-validated test object33.
Scans were done at baseline and at days 22–28 after treatment. Test object
measurements for quality assurance of quantitative metrics were undertaken
regularly to ensure quality control. The coefficient of variation (CV) for ADC
across multiple time-points was 0.4% and 1.4% (Philips and GE, respectively).
ADC CV between the two sites was 3.9%. MRI examinations consisted of DW-MRI
of the abdomen and pelvis as per the protocols below, followed by T1-weighted and
T2-weighted imaging in matched positions.
DW-MRI analysis. On the pre- and post-treatment scans, regions-of-interest
(ROI) were drawn around the tumor on the high b-value (b= 800 s/mm2)
diffusion-weighted images by a board-certified radiologist in OsiriX version 9.0.
ROIs were then copied onto the corresponding ADC maps which were generated
on a voxel-by-voxel basis from a mono-exponential fit to the data as described by S
(b)= S(0) exp(−b × ADC)24.
Tissue CRABP2, FABP5. Hematoxylin and eosin quality control of remaining
tissue from diagnostic material by a board-certified pathologist for histological/
Fig. 4 Biomarkers for STARPAC clinical trial. aMRI sequences as indicated with primary pancreatic tumor (red arrow) and liver metastasis (white arrow)
in T2-weighted images for localization, both lesions demonstrating change in the apparent diffusion coefficient (ADC) within these tumors, after just
1 month of treatment, indicative of an increased mobile water content due to reduction in dense cellularity with a rim of peripheral restricted tissue
represents residual tumor. Summary statistics of changes in tumor volume (b), ADC values (c), and D values (d) between pre-treatment (baseline) and
post-first-cycle (days 21–28) of treatment. Summary data as mean ± SEM. Data points represent values from individual patients. Two-tailed Wilcoxon
matched-pairs sign-rank test. e Representative images of co-immuno-fluorescent images of pancreatic cancer biopsies prior to commencement of
treatment, to assess prevalence of cellular retinoic acid-binding protein 2 (CRABP2) and fatty acid-binding protein 5 (FABP5), as indicated with co-staining
with either cytokeratin (CK) or alpha-smooth muscle actin (αSMA) respectively, to demonstrate a 3+ stain for both CRABP2 and FABP5 in cancer cells
and cancer-associated fibroblasts (CAF). Scale bar: 100 µm. f, g These quantifications (range 0 to 3+) were then assessed for all evaluable biopsies (n=
15) from single representative image using appropriate tissue controls and categorized according to disease control/progressive disease. Chi-square test.
d.f.= 3. h Measurement of serum PTX3 by ELISA (GCLP standards, CV 0.17) in patients before (Base) and 5 h after (Post) taking ATRA in the first cycle
(C1) on days 1, 8, and 15. i Measurement of serum PTX3 5 h after taking ATRA on the first day of each cycle (1–6). Each point represents an individual
patient. h, i Box (median ± interquartile range) and whisker (full range). Individual measurements per patient represented as a dot derived from mean of
two readings. Two-tailed Wilcoxon matched-pairs signed-rank test.
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cytological confirmation demonstrate that there was either inadequate tissue
(n= 7) or only cancer cells without stroma (n= 5) to carry further analysis. Hence
formalin-fixed paraffin-embedded sections from 15 patients were dewaxed and
rehydrated, antigen retrieved (0.1 M citrate buffer, pH 6, microwave, 20 m),
blocked (1 h, RT, 2% bovine serum albumin, 0.02% fish skin gelatin, 10% FBS, 5%
goat serum) before use of primary antibodies at 4 °C overnight, followed by
appropriate fluorescent-labeled secondary antibodies27. The nuclei were then
counterstained with DAPI. Organotypic sections, from as previous experiments7,
were used for positive and negative staining controls (Supplementary Table 11).
Controls were uniformly negative with appropriate isotype-specific immunoglo-
bulin at matching dilutions.
Immunofluorescent images were taken using the Zeiss Confocal LSM510
microscope at ×20 magnification, and images were visualized using Zeiss Zen
2.3 software. The green channel represented either α-smooth muscle actin or
cytokeratin; the red channel represented FABP5 or CRABP2. The intensity of
fluorescence in the green/red channel for respective molecules was given a semi-
quantitative value, ranging from negative “−” through to strongly positive “+++”.
There were four categories of fluorescence intensity: −, +, ++, +++. The
threshold gain and offset was set according to the intensity of the green/red channel
in the organotypic cultures, and ensured minimal inter-day variability
(Supplementary Figs. 7 and 8).
Plasma PTX3. PTX3 levels were quantified with a sandwich enzyme-linked
immunosorbent assay (ELISA) using in-house validated protocol based on a
monoclonal antibody MNB4 (Enzo Life Sciences ALX-804-464-C100)34. Plasma
PTX3 concentrations were quantified using the sandwich ELISA as follows: 96-
well-ELISA plates were coated with MNB4 anti-human PTX3 antibody (100 ng/
well) diluted in coating buffer (15 mM carbonate buffer, pH 9.6, overnight, 4 °C),
washed, blocked (5% dry milk in washing buffer, 2 h, room temperature), washed,
and incubated with either 50 μL of diluted plasma (1:3 dilution in PBS without
Ca2+ Mg2+ and 2% BSA) or 50 μL recombinant human PTX3 standards
(0.31–20 ng/mL), all in duplicates for 2 h at 37 °C. After two washes, 50 ng/mL of
biotinylated PTX3 (Enzo Life Sciences, cat. ALX-210-365B) antibody was added in
each well for 1 h at RT, washes and color realized by 100 μL/well streptavidin-
horseradish peroxidase (Amersham, cat. RPN4401V) diluted 1:4000 for 1 h at RT.
After further washes 100 μL of chromogen substrate (ThermoFisher cat. 34028B)
was added and plates were read after 15 min at 450 nm in a plate-reader. Poly-
nomial regression graphs were constructed for standard curves. Plasma samples of
each patient time-point were thawed only once and assayed, maintaining a chain of
custody, in duplicate. ELISA was conducted in a blinded manner, and inter-day
variability standard patient samples were used with CV 0.17 (Supplementary
Fig. 9). Patient variables were unblinded after submission of readouts.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data supporting this Article are available within the Article, Supplementary
Information, or available from the authors upon request.
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